VA-CIG as initial intensive therapy for fit adults with acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, single-arm Phase 2 trial testing the VA-CIG induction regimen (venetoclax + azacitidine + idarubicin + low-dose cytarabine + G-CSF) in patients with newly diagnosed AML who are eligible for intensive chemotherapy. Eligible patients are 18–70 years old with ECOG performance status ≤2 and no prior AML-directed therapy, and they receive the combination regimen with planned monitoring for response and toxicity. Primary outcomes focus on remission rates and safety, with secondary measures including survival endpoints compared against historical controls. The single-arm design means there is no randomized comparator and results will inform whether larger controlled trials are warranted.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of acute myeloid leukemia (AML, excluding acute promyelocytic leukemia) confirmed by morphology, immunophenotyping and molecular genetics, in accordance with the WHO 2022 diagnostic criteria for AML;
* Age 18-70 years, with no gender restriction;
* No prior AML-related treatment has been received; exceptions are made for the use of hydroxyurea or similar agents during the diagnostic screening phase to control peripheral blood leukemic blasts;
* Patients must be assessed as tolerable to intensive chemotherapy regimens; evaluation of tolerance to intensive chemotherapy shall be performed in accordance with the Ferrara 2013 criteria (Appendix A);
* Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;
* Serum creatinine ≤ 2.0 × upper limit of normal (ULN), or creatinine clearance \> 40 mL/min calculated by the Cockcroft-Gault formula for glomerular filtration rate (GFR);
* Total bilirubin ≤ 2 × ULN, and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 × ULN;
* Left ventricular ejection fraction (LVEF) ≥ 45%, or LVEF measured by echocardiography (ECHO) within the normal range;
* Expected survival \> 3 months.

Exclusion Criteria:

* Subjects with a history of myeloproliferative neoplasms (MPNs), including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation, and acute myeloid leukemia (AML) with BCR-ABL1 translocation;
* Patients with a prior history of venetoclax or azacitidine (Aza) treatment for other diseases;
* Known hypersensitivity to any component of the investigational medicinal products;
* History of other concurrent malignancies within 2 years prior to enrollment, except:

Adequately treated carcinoma in situ of the cervix or breast; Basal cell carcinoma or localized squamous cell carcinoma of the skin; Previously controlled malignancies treated with radical surgical resection (or other curative modalities), etc.

* Presence of uncontrolled severe infection or active bleeding;
* Pregnant or lactating women;
* Subjects with active, treatment-uncontrolled viral infection caused by HIV, hepatitis B virus, or hepatitis C virus;
* Subjects with evidence of central nervous system leukemia before treatment initiation;
* Women of childbearing potential who do not agree to use at least one reliable contraceptive method from Day 1 of the study until 90 days after the last dose of study medication; sexually active male subjects who do not agree to use contraceptive measures from Day 1 of the study until 90 days after the last dose of study medication; male subjects who do not agree to refrain from sperm donation from the start of study drug administration until at least 90 days after the last dose;
* Subjects with epilepsy requiring pharmacotherapy, dementia, or other abnormal psychiatric conditions that impair the ability to understand or comply with the study protocol;
* Presence of psychiatric disorders or cognitive impairment that prevents cooperation with treatment and follow-up; conditions limiting oral drug intake or gastrointestinal absorption.

Where it's running

• Chinese PLA General Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Dr. Gao Xiaoning, Chief Physician, Professor
• Email: gaoxn@263.net
• Phone: 86+01066947169

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Interferon-α Maintenance for Favorable-Risk AML

  This study tests pegylated interferon alfa-2b as maintenance therapy to see if it helps keep favorable-risk AML in remission after initial treatment.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07925554

• CARCIK-CD123/33 cells for relapsed or refractory AML and BPDCN in children and adults

  This trial tests CARCIK-CD123/33 cell therapy to see if it is safe and feasible for people with relapsed or refractory AML or BPDCN, including kids and adults, before planned stem cell transplant.

  Recruiting Phase 1/2 Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Monza, MB and 1 other locations · NCT07877610

• Soursop tea in relapsed/refractory AML or multiple myeloma

  This pilot study tests whether drinking tea made from soursop leaves can help reduce cancer cells in people with relapsed or refractory AML or MM.

  Recruiting Early Phase 1 Cooper Norcross Health · Camden, New Jersey · NCT07771803

• CHM-029 in adults with certain AML mutations or rearrangements

  This study tests whether an oral medicine called CHM-029 is safe and shows signs of activity in adults with relapsed or treatment-resistant AML with specific genetic features.

  Recruiting at 8 sites Phase 1 Charm Therapeutics · Duarte, California and 7 other locations · NCT07751991

• Venetoclax with Decitabine vs Venetoclax with DA vs standard DA in newly diagnosed AML

  This trial tests three induction regimens in adults with newly diagnosed AML to see which combination best balances effectiveness and tolerability.

  Recruiting Phase 3 The Second Affiliated Hospital of Kunming Medical University · Kunming, Yunnan · NCT07712848

• Ivosidenib as maintenance therapy for IDH1-mutated AML or high-risk MDS in patients ineligible for transplant

  This study tests whether continuing ivosidenib after induction helps people with IDH1-mutated AML or high-risk MDS who can’t have a transplant, to see if it helps keep cancer from returning.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07607418

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.